Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Predict S.P.A. Class B ( (IT:PRE) ) has issued an update.
Predict S.p.A. announced the acceptance of 300,000 ordinary shares under its Stock Grant Plan 2025, to be completed by December 31, 2025. This initiative will lead to a change in share capital, with necessary formalities to be filed at the Bari Business Register, potentially impacting the company’s financial structure and stakeholder interests.
The most recent analyst rating on (IT:PRE) stock is a Buy with a EUR1.45 price target. To see the full list of analyst forecasts on Predict S.P.A. Class B stock, see the IT:PRE Stock Forecast page.
More about Predict S.P.A. Class B
Predict S.p.A., founded in 2008 in Bari, is an innovative SME in the healthcare sector, focusing on in vivo diagnostics through ultrasound and radiological equipment distribution, and developing technologies in breath analysis and digital healthcare. The company operates through four Strategic Business Units, offering solutions like Mistral for non-invasive oncological screening, Aphel for robotic patient support, and Optip for remote medical consultations. Predict collaborates with leading Italian university hospitals and research institutes.
Average Trading Volume: 40,821
Technical Sentiment Signal: Strong Buy
See more insights into PRE stock on TipRanks’ Stock Analysis page.